KIT and neoplasm: Finally, we performed a separate experiment to examine the effect of twice daily, orally administered masitinib at 100 mg/kg on mice having large Δ27 KIT-expressing tumours (average tumour volume 500 mm3, 26 days post implantation of tumour cells).